Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix.
Adenocarcinoma, Mucinous
/ diagnosis
Adult
Biomarkers, Tumor
/ genetics
Cervix Uteri
/ pathology
Cyclin-Dependent Kinase Inhibitor p16
/ genetics
Diagnosis, Differential
Disease-Free Survival
Female
Humans
Hysterectomy
Middle Aged
Mutation
Neoplasm Invasiveness
/ genetics
Retrospective Studies
Tumor Suppressor Protein p53
Uterine Cervical Neoplasms
/ diagnosis
Uterus
cervix
gastric-type mucinous carcinoma
immunohistochemistry
targeted sequencing
usual-type endocervical adenocarcinoma
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
05
05
2020
revised:
23
05
2020
accepted:
22
06
2020
entrez:
30
8
2020
pubmed:
30
8
2020
medline:
6
5
2021
Statut:
ppublish
Résumé
We investigated differences in the clinicopathological and molecular characteristics between gastric-type mucinous carcinoma (GMC) and usual-type endocervical adenocarcinoma (UEA). We collected the clinicopathological information and performed targeted genomic sequencing analysis. GMCs exhibited significantly deeper invasion depth, larger horizontal spread, more advanced stage, more frequent distant metastasis, and more frequent parametrial and vaginal extension. Disease-free survival time of GMC patients was significantly shorter than that of UEA patients. GMCs displayed mutant p53 immunostaining pattern, whereas UEAs exhibited p16 block positivity. GMCs harbored mutations in KRAS, TP53, NF1, CDKN2A, STK11, and ARID1A. One GMC exhibited MDM2 amplification. In contrast, UEAs harbored mutations in HRAS, PIK3CA, and BRCA2. Two UEAs were found to have novel TP53 mutations. GMC is associated with more aggressive behavior than UEA. Distinctive p53 and p16 immunostaining patterns enable differential diagnosis. GMC and UEA exhibit genetic heterogeneity with potentially actionable molecular alterations.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We investigated differences in the clinicopathological and molecular characteristics between gastric-type mucinous carcinoma (GMC) and usual-type endocervical adenocarcinoma (UEA).
PATIENTS AND METHODS
METHODS
We collected the clinicopathological information and performed targeted genomic sequencing analysis.
RESULTS
RESULTS
GMCs exhibited significantly deeper invasion depth, larger horizontal spread, more advanced stage, more frequent distant metastasis, and more frequent parametrial and vaginal extension. Disease-free survival time of GMC patients was significantly shorter than that of UEA patients. GMCs displayed mutant p53 immunostaining pattern, whereas UEAs exhibited p16 block positivity. GMCs harbored mutations in KRAS, TP53, NF1, CDKN2A, STK11, and ARID1A. One GMC exhibited MDM2 amplification. In contrast, UEAs harbored mutations in HRAS, PIK3CA, and BRCA2. Two UEAs were found to have novel TP53 mutations.
CONCLUSION
CONCLUSIONS
GMC is associated with more aggressive behavior than UEA. Distinctive p53 and p16 immunostaining patterns enable differential diagnosis. GMC and UEA exhibit genetic heterogeneity with potentially actionable molecular alterations.
Identifiants
pubmed: 32859641
pii: 17/5/627
doi: 10.21873/cgp.20219
pmc: PMC7472441
doi:
Substances chimiques
Biomarkers, Tumor
0
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-641Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Gynecol Oncol. 2000 Aug;78(2):97-105
pubmed: 10926787
Anticancer Res. 2018 May;38(5):2779-2786
pubmed: 29715099
Pathol Oncol Res. 2019 Jan;25(1):123-130
pubmed: 28990139
Oncotarget. 2016 Nov 8;7(45):74152-74161
pubmed: 27708230
Biomed Pharmacother. 2018 Jan;97:1595-1602
pubmed: 29793321
Anticancer Res. 2017 Oct;37(10):5525-5531
pubmed: 28982866
Int J Gynecol Cancer. 2018 Jul;28(6):1203-1210
pubmed: 29683881
Mod Pathol. 2019 Dec;32(12):1823-1833
pubmed: 31308508
Am J Surg Pathol. 2017 Jul;41(7):896-905
pubmed: 28418994
Gynecol Oncol. 2018 Dec;151(3):414-421
pubmed: 30314669
Hum Pathol. 2017 Dec;70:6-13
pubmed: 28601659
Anticancer Res. 2019 Feb;39(2):663-670
pubmed: 30711943
Anticancer Res. 2018 Mar;38(3):1767-1774
pubmed: 29491115
Cancer Detect Prev. 2004;28(6):461-4
pubmed: 15582270
Int J Gynecol Pathol. 2020 Sep;39(5):436-442
pubmed: 31517653
Int J Gynecol Pathol. 2018 Jan;37(1):17-21
pubmed: 28319574
Gynecol Oncol. 2019 Apr;153(1):13-19
pubmed: 30709650
Cancers (Basel). 2019 Nov 22;11(12):
pubmed: 31766622
Pathology. 2018 Feb;50(2):238-256
pubmed: 29373116
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):645-50
pubmed: 19827887
Pathology. 2018 Feb;50(2):122-133
pubmed: 29233547
Am J Surg Pathol. 2017 May;41(5):696-705
pubmed: 28296678
Virchows Arch. 2018 Aug;473(2):165-175
pubmed: 29926183
Am J Surg Pathol. 2018 Feb;42(2):214-226
pubmed: 29135516
J Med Genet. 2010 Jun;47(6):421-8
pubmed: 20522432
Anticancer Res. 2019 Jun;39(6):2883-2889
pubmed: 31177126
Anticancer Res. 2017 Dec;37(12):6697-6703
pubmed: 29187446
Oncotarget. 2016 Jul 26;7(30):48120-48129
pubmed: 27329721
Histopathology. 2010 Jul;57(1):46-54
pubmed: 20557372
Virchows Arch. 2017 Sep;471(3):363-373
pubmed: 28702779
Radiat Oncol J. 2015 Jun;33(2):109-16
pubmed: 26157680
J Neurooncol. 2019 May;142(3):445-454
pubmed: 30710203
CMAJ. 2001 Apr 17;164(8):1151-2
pubmed: 11338801
Am J Pathol. 2010 Nov;177(5):2169-75
pubmed: 20829441
Am J Surg Pathol. 2019 Jan;43(1):12-25
pubmed: 29189288
Am J Surg Pathol. 2014 Mar;38(3):370-6
pubmed: 24145653
Anticancer Res. 2017 May;37(5):2437-2444
pubmed: 28476811
Anticancer Res. 2017 Dec;37(12):7063-7068
pubmed: 29187496
Am J Surg Pathol. 2015 Nov;39(11):1449-57
pubmed: 26457350
Leukemia. 2011 May;25(5):856-67
pubmed: 21394100
J Pathol Transl Med. 2017 Sep;51(5):456-462
pubmed: 28934825
Gynecol Oncol. 2013 Jan;128(1):44-48
pubmed: 23138134
Am J Surg Pathol. 2016 May;40(5):636-44
pubmed: 26685087
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Surg Pathol. 2007 May;31(5):664-72
pubmed: 17460448